| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 40,216 | 40,216 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 14 | 14 |
| Net cash provided by (used in) financing activities | 14 | 14 |
| Net increase (decrease) in cash and cash equivalents | 15,200 | 20,053 |
| Cash and cash equivalents at beginning of period | 37,573 | - |
| Cash and cash equivalents at end of period | 52,773 | - |
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)